The short version of Angiotensin IV analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Teva and Sandoz are by far the largest generics companies. They differ from their competitors not only in sales revenues but also because they are backwards integrated and have proprietary drugs in their portfolios. They also vie for the biosimilars market. Several thousand small or virtual pharma companies focus on R&D of just a few lead compounds. They typically originate mostly from academia. Therefore, their R&D strategy is more focused on the elucidation of the biological roots of diseases rather than developing synthesis methods.
Tapentadol was invented at the German pharmaceutical company Grünenthal in the late 1980s led by Helmut Buschmann; the team started by analyzing the chemistry and activity of tramadol, which had been invented at the same company in 1962. Tramadol has several enantiomers, and each forms metabolites after processing in the liver. These tramadol variants have varying activities at the μ-opioid receptor, the norepinephrine transporter, and the serotonin transporter, and differing half-lives, with the metabolites having the best activity. Using tramadol as a starting point, the team aimed to discover a single molecule that minimized the serotonin activity, had strong μ-opioid receptor agonism and strong norepinephrine reuptake inhibition, and would not require metabolism to be active; the result was tapentadol. In 2003 Grünenthal partnered with two Johnson & Johnson subsidiaries, Johnson & Johnson Pharmaceutical Research and Development and Ortho-McNeil Pharmaceutical to develop and market tapentadol; Johnson & Johnson had exclusive rights to sell the drug in the US, Canada, and Japan while Grünenthal retained rights elsewhere. In 2008 tapentadol received approval by the US Food and Drug Administration; in 2009 it was classified by US Drug Enforcement Agency as a Schedule II drug, and entered the US market. Tapentadol was reported to be the "first new molecular entity of oral centrally acting analgesics" class approved in the United States in more than 25 years. In 2010 Grünenthal granted Johnson & Johnson the right to market tapentadol in about 80 additional countries.
Abu Omar al-Shishani Abu Sayfullah Shishani Abu Said Shishani Ahmad Shishani Abu Abdullah Shishani Al Bara Shishani Abu Ibrahim Shishani Abu Umar Grozny Musa Abu Yusuf Shishani Hayrullah Shishani Abdullah Shishani Abu Hafs Shishani Adam Shishani Abdul-Halim Shishani Hattab Shishani Abdullah Abu Muhammad Shishani Abdul-Vahhab Shishani Muhammad Shishani Abu Hisham Shishani Abu Anas Shishani Abu Shamil Shishani Jundullah Shishani
=== Pleural abnormalities === Fluid in space between the lung and the chest wall is termed a pleural effusion. There needs to be at least 75 mL of pleural fluid in order to blunt the costophrenic angle on the lateral chest radiograph and 200 mL of pleural fluid in order to blunt the costophrenic angle on the posteroanterior chest radiograph. On a lateral decubitus, amounts as small as 50ml of fluid are possible. Pleural effusions typically have a meniscus visible on an erect chest radiograph, but loculated effusions (as occur with an empyema) may have a lenticular shape (the fluid making an obtuse angle with the chest wall). Pleural thickening may cause blunting of the costophrenic angle, but is distinguished from pleural fluid by the fact that it occurs as a linear shadow ascending vertically and clinging to the ribs.
Sources: en.wikipedia.org
==== Encapsulated catalysts ==== The MOF encapsulation approach invites comparison to earlier studies of oxidative catalysis by zeolite-encapsulated Fe(porphyrin) as well as Mn(porphyrin) systems. The zeolite studies generally employed iodosylbenzene (PhIO), rather than TPHP as oxidant. The difference is likely mechanistically significant, thus complicating comparisons. Briefly, PhIO is a single oxygen atom donor, while TBHP is capable of more complex behavior. In addition, for the MOF-based system, it is conceivable that oxidation proceeds via both oxygen transfer from a manganese oxo intermediate as well as a manganese-initiated radical chain reaction pathway. Regardless of mechanism, the approach is a promising one for isolating and thereby stabilizing the porphyrins against both oxo-bridged dimer formation and oxidative degradation.
On October 10, 1868, Carlos Manuel de Céspedes freed his slaves and declared revolution against Spain at the Cry of Yara. de Céspedes was also the Worshipful Master of Logia Buena Fe (English: Good Faith Lodge) at Manzanillo, a Lodge within GOCA. Around this time, the first "non white" Cubans were initiated as Freemasons into the revolutionary Masonic Lodges. The Colonial government saw the Freemasonry movement in Cuba as inherently associated with the revolutionary movement. They feared that gatherings of Freemasons could be used as cover for the revolutionary cause, and went on a renewed campaign to fully suppress Freemasonry in the colony. On the same day that the war was declared, GOCA was dissolved in Havana. Many of the revolutionaries who signed the Guáimaro Constitution were also Freemasons. However, almost all of the revolutionary Freemasons during this war were former members of GOCA, as in the beginning of this war, the Colon Freemasons were largely supportive of Spanish rule. With the dissolution of GOCA, its former members founded individual Lodges during the war. Famously, Carlos Manuel de Céspedes established the Independence Lodge. Tínima Lodge and Camagüey Lodge were also created around this time. The Grand Lodge of Colon was absorbed by the Supreme Council in Santiago de Cuba, but it could no longer operate at full capacity, and could not rely on spiritual support from abroad. Spanish spies were monitoring traffic from the United States.
Whereas medical school teaches physicians a broad range of medical knowledge, basic clinical skills, and supervised experience practicing medicine in a variety of fields, medical residency gives in-depth training within a specific branch of medicine.
Sources: en.wikipedia.org
Kay Mason Billig, the leader of Norfolk County Council, apologises "unreservedly" for posting a picture of a steak dinner on Facebook with the words: "Wonder what all the poor people are doing?" 21 June – An Ipsos poll gives Reform UK its highest poll rating so far, with 34%, nine points ahead of Labour on 25%, and 19 points ahead of the Conservatives on 15%. 22 June – Former Pembrokeshire councillor Andrew Edwards is disqualified from holding public office for four years over a racist voice note he posted on WhatsApp. 23 June – Reform UK announces that it would give people with non-domicile tax status the chance to avoid some UK taxes by paying a £250,000 fee, with the proceeds going to people on the lowest incomes. 25 June – Buckingham Palace confirms that US President Donald Trump will make a full state visit to the UK later in the year. Starmer says the government will press ahead with a parliamentary vote on welfare reform on 1 July, despite a growing rebellion among backbench Labour MPs that could see the proposed legislation defeated. Reform councillor Rob Howard resigns as leader of Warwickshire County Council citing his health, and leaving his 18-year-old deputy, George Finch, as interim leader. 29 June – Conservative MP George Freeman refers himself to the Parliamentary Commissioner for Standards after allegations a company he works for asked him to ask a question in Parliament. 30 June – Two Reform UK breakaway parties are formed by past Reform members. Advance UK is established by Ben Habib, and Restore Britain is started by Rupert Lowe.
There are debates over other potential causes such as nighttime drops in blood pressure, as well as the hypothesis that the optic disc's ability to regulate its blood flow may be compromised. Some researchers have even suggested that blockages in the veins could be responsible. One hypothesis suggests that the underlying cause may be a subtle decrease in blood flow to the optic nerve, which is enough to cause swelling of the nerve fibers but not severe enough to disrupt vision through tissue death and permanent damage to the optic nerve. When considering the possible causes for spontaneous NAION, the list includes other conditions like arteritic anterior ischemic optic neuropathy (associated with inflammation of arteries), optic neuritis (inflammation of the optic nerve), infiltrative and compressive types of optic neuropathy (where the optic nerve is invaded or pressed upon by abnormal substances or structures), diabetic papillopathy (swelling of the optic disc in diabetes), radiation-induced damage to the optic nerve, neuroretinitis (inflammation of the optic nerve and retina), and swelling of the optic disc linked with retinal diseases like central retinal vein occlusion.
== Practical uses == While at first the chemical garden may appear to be primarily a toy, some serious work has been done on the subject. For instance, this chemistry is related to the setting of Portland cement, the formation of hydrothermal vents, and the corrosion of steel surfaces on which insoluble tubes can be formed. The nature of the growth of the insoluble silicate tubes formed within chemical gardens is also useful in understanding classes of related behavior seen in fluids separated by membranes. In various ways, the growth of the silicate tubes resembles the growth of spikes or blobs of ice extruded above the freezing surface of still water, the patterns formed by drying gum as it drips from wounds in trees such as Eucalyptus, and the way molten wax forms twig-like growths, either dripping from a candle, or floating up through cool water. The fundamental principles governing their self-assembly and membrane dynamics have been extensively leveraged across multiple scientific disciplines, including biomedicine (e.g., engineering cellular scaffolds and bone substitute materials), and astrobiology (e.g., modeling prebiotic compartmentalization and the emergence of life in hydrothermal vent environments). Chemobrionic materials have also been investigated as active layers in memristive devices for neuromorphic computing.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.